Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Nikkei hobbled by trade worries, disappointing earnings

Wed, 15th May 2019 04:04

* Nikkei down slightly after 7 losing sessions

* Uncertainties over U.S.-China standoff keep investors onedge

* Takeda Pharma, Nissan sink after earnings shock

* Mitsubishi Estate jumps on share buyback, governancereform

By Hideyuki Sano

TOKYO, May 15 (Reuters) - Japanese share prices were cappedon Wednesday by concerns about the broader economic impact ofrising tensions between Washington and Beijing, while an arrayof disappointing corporate earnings added to the downcast mood.

The Nikkei share average was off 0.08% at 21,051,after spending much of the session under water, even after sevenstraight days of losses until Tuesday.

The broader Topix, which hit a four-month low theprevious day, was down 0.03% at 1534.51.

Trade-sensitive stocks came under pressure, even thoughglobal shares have somewhat stabilised after U.S. PresidentDonald Trump made optimistic comments on trade talks with China.

Trump insisted trade discussions with China had notcollapsed, denying talks with Beijing had broken down afterWashington punctuated two days of negotiations last week withanother round of tariffs on Chinese imports.

"Although we saw some recovery in share prices after Trump'scomments, there are heightened uncertainties over trade, whichare negative for stocks," said Shusuke Yamada, chief Japan FXand equity strategist at Bank Of America Merrill Lynch.

Steelmakers fell 2.4% while shippersdropped 0.9%.

Not helping sentiment was Japanese corporate earnings, withnet profits falling almost 5.0% from a year earlier inJanuary-March, according to Okasan Securities.

Takeda Pharmaceutical fell as much as 8.6%. Japan'sbiggest drugmaker forecast an unexpected operating loss for thecurrent year due to costs associated with the $59 billionpurchase of Shire Plc.

That helped to bring down Tokyo Stock Exchange's drugmakersubindex 3.1%, making it the worst performer.

Nissan Motor slumped as much as to 8.0% to itslowest levels since late December 2012, after the carmakerforecast the weakest profit outlook in more than a decade.

"The earnings results suggested that the company is in muchworse shape than I have imagined," said Hiroshi Masushima,market analyst at Monex Securities.

The carmaker, hit by former chairman Carlos Ghosn's arrestlast year and troubles at its North American business, also saidits dividend will be cut about 30% in another blow to investorsas its hefty payouts have been the only major attraction.

H2O Retailing fell as much as 12.7% to seven-yearlows as the mid-tier department store operator posted weakearnings and guidance.

On the upside, Mitsubishi Estate jumped as much as11.2% after the real estate developer announced its first sharebuyback and a plan to abolish anti-takeover steps.

Decliners slightly outnumbered advancers by 1065 to 992.(Editing by Shri Navaratnam)

More News
17 Feb 2017 11:03

Britain's FTSE set for week of modest gains, pharmas lead

(ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets) * FTSE 100 flat, set for third week of gains * Retail sales drop weighs on pound * Copper miners weigh while precious miners edge

Read more
16 Feb 2017 17:05

LONDON MARKET CLOSE: Sterling Rebound, Ex-Divs Send UK Stocks Lower

Read more
16 Feb 2017 15:22

UPDATE 1-Pharma group Shire produces top-of-the-range earnings

* FY earnings rise 12 pct to come in at top of range * Sees strong product sales and earnings growth in 2017 * Shares rise 6 pct (Adds CEO comments, analyst reaction, shares) By Paul Sandle LONDON, Feb 16 (Reuters) - Pharmaceuticals group Shire on Thursday said it was e

Read more
16 Feb 2017 12:30

Shire earnings beat estimates and remains 'extremely optimistic' for 2017

(ShareCast News) - Shire has reported fourth quarter sales and earnings that beat City estimates, with the drugmaker confident of generating strong top- and bottom-line growth in 2017. Revenues for the quarter came in £3.81bn, versus the consensus $3.77bn, while earnings per share of $3.37 beat the

Read more
16 Feb 2017 12:17

Pharma group Shire posts earnings rise at top of guidance

LONDON, Feb 16 (Reuters) - Pharmaceuticals group Shire reported a 12 percent rise in full-year earnings after what it said was a transformational year marked by its largest acquisition to date, adding that it is extremely optimistic on long-term growth prospects. The London-listed company

Read more
7 Feb 2017 20:25

UPDATE 2-FTC sues Shire ViroPharma for fighting generic entry of Vancocin

(Adds that Shire will fight lawsuit, details from complaint) By Diane Bartz WASHINGTON, Feb 7 (Reuters) - The U.S. Federal Trade Commission filed a complaint against Shire ViroPharma on Tuesday, accusing it of hijacking a government channel designed to flag safety issues by using it t

Read more
7 Feb 2017 18:28

FTC sues Shire ViroPharma for fighting generic entry of Vancocin

WASHINGTON, Feb 7 (Reuters) - The U.S. Federal Trade Commission filed a complaint against Shire ViroPharma on Tuesday, accusing it of abusing government processes in order to fend off generic competition to its antibiotic Vancocin HCI, the agency said in a statement. The company filed repea

Read more
1 Feb 2017 15:46

Sector movers: Cyclicals bounce back, Evraz in the lead

(ShareCast News) - There was a clear split in the market on Wednesday as cyclicals bounced back and the more defensive segments of the market were relegated to the bottom of the pile. Thus, shares in Prudential and Aviva were to be seen pacing gains among life insurers as yields on benchmark 10-year

Read more
20 Jan 2017 08:51

Pharma CEOs in Davos put brave face on Trump presidency

By Ben Hirschler DAVOS, Switzerland, Jan 20 (Reuters) - Leaders of the global pharmaceutical industry, blasted by incoming U.S. President Donald Trump for "getting away with murder" on drug prices, are putting a brave face on the challenges in their biggest market. The following are c

Read more
13 Jan 2017 16:54

Britain's FTSE hits record highs, extends historic winning streak

* FTSE 100 touches new record, sets 14th day of gains * Pharmaceuticals rebound after Trump scare * Housebuilders top the index * ITV buoyed by broker optimism (Adds details and updates prices at close) By Kit Rees and Helen Reid LONDON, Jan 13 (Reuters) - Britain'

Read more
11 Jan 2017 15:27

U.S. says Shire subsidiaries to pay $350 mln to settle false claims act allegations

WASHINGTON, Jan 11 (Reuters) - Shire PLC subsidiaries will pay $350 million to settle U.S. federal and state False Claims Act allegations related to unlawful methods to push "Dermagraft," a treatment for diabetic foot ulcers, the U.S. Justice Department said in a statement on Wednesday. "Th

Read more
22 Dec 2016 06:11

Roche's emicizumab haemophilia drug succeeds in trial

ZURICH, Dec 22 (Reuters) - Roche Holding AG's emicizumab drug for treating haemophilia A met its primary endpoint in a phase III study, the Swiss drugmaker said on Thursday. "The study showed a statistically significant reduction in the number of bleeds over time in people treated with emi

Read more
16 Dec 2016 14:11

FTSE 100 movers: Pharmaceutical stocks lead FTSE's rally

(ShareCast News) - The FTSE 100 rose 0.11% to 7,006.73 points on Friday afternoon with pharmaceutical stocks leading the way. Hikma Pharmaceuticals, Shire and Astrazeneca rallied on a positive read-across following reports Sanofi is in advanced talks to acquire Actelion. The companies are said to b

Read more
16 Dec 2016 09:29

BROKER RATINGS SUMMARY: Shore Upgrades Downtrodden IG And CMC Markets

Read more
7 Dec 2016 17:15

UPDATE 1-Britain's FTSE hits one-month high as banks and miners lead cyclical charge

* FTSE 100 up 1.8 pct * Banks hit 1 1/2-year high * Rio benefits from Credit Suisse upgrade * WPP falls on reported DOJ probe (Recasts, adds detail and updates prices at close) By Kit Rees and Alistair Smout LONDON, Dec 7 (Reuters) - Britain's top share index rose

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.